Physician profile
Amanda M Schmidtmann
NPI 1063854446
$3,660.45
in general payments reported to CMS, 2019-2025
38 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $275 · 2022: $536 · 2023: $1,521 · 2024: $1,138 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,824 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,824.41 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $594.33 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $559.96 | 2022-2024 | |
| Glaxosmithkline, LLC. | $282.39 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $258.95 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $241.07 | 2022-2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $211.26 | 2022-2024 | |
| Novo Nordisk INC | $144.23 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.67 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.63 | 2022-2024 | Jardiance, Synjardy |
| Amgen INC. | $81.20 | 2023-2025 | Evenity, Prolia, Prolia |
| Grifols USA, LLC | $74.78 | 2022-2023 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $68.84 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $68.51 | 2023-2024 | Quviviq |
| Seqirus USA INC | $68.04 | 2022-2024 | Fluad, Flucelvax |
| Boston Scientific Corporation | $59.77 | 2025 | Wavewriter Alpha Prime 16 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $56.33 | 2024 | (Ck7) Extended Holter |
| Abbott Laboratories | $55.79 | 2022-2023 | Aveir, Freestyle Libre 2 |
| Currax Pharmaceuticals LLC | $52.58 | 2022-2023 | Nexletol, Nexlizet, Contrave |
| Sanofi Pasteur INC. | $51.47 | 2023-2024 | |
| Si-Bone, INC. | $48.26 | 2023-2024 | |
| Astellas Pharma US INC | $45.33 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $43.86 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $42.68 | 2022 | |
| Halozyme INC | $40.82 | 2023 | |
| Gilead Sciences, INC. | $38.92 | 2023-2024 | |
| Nevro Corp. | $30.48 | 2022 | |
| Merck Sharp & Dohme LLC | $21.33 | 2022 | |
| Phadia US INC. | $19.04 | 2024 | Immunocap |
| Biowound Solutions, INC. | $18.98 | 2025 | Bio-Connekt |
| Saluda Medical Americas, INC. | $18.89 | 2023 | Evoke Scs |
| Verity Pharmaceuticals INC. | $17.63 | 2024 | Tlando |
| Avanir Pharmaceuticals, INC. | $17.56 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.48 | 2022 | |
| Pfizer INC. | $16.73 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $16.22 | 2023 | Seglentis |
| Acerus Pharmaceuticals Corporation | $14.76 | 2022 | |
| Antares Pharma, INC. | $14.55 | 2023 | Tlando, Nocdurna, Xyosted |
| Tolmar, INC. | $13.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Schmidtmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.